UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|||
(State or Other Jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
of Incorporation) |
|
|
|
Identification No.) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||
(Address of Principal Executive Offices) |
|
|
|
(Zip Code) |
Registrant’s telephone number, including area code: (
N/A
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
The |
||
|
|
The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On May 9, 2022, Clene Inc. (the “Company”) issued a press release announcing its first quarter operating and financial results for its quarter ended March 31, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Current Report”) and is incorporated herein by reference.
The information furnished in this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933 (the “Securities Act”), as amended, regardless of any general incorporation language in any such filings, except as shall be expressly set forth by specific reference in such a filing.
Item 7.01 Regulation FD Disclosure.
In connection with the May 9, 2022 press release announcing the Company’s first quarter operating and financial results for its quarter ended March 31, 2022, the Company released an updated corporate presentation (the “Corporate Presentation”) on its website, invest.clene.com. A copy of the Corporate Presentation is furnished as Exhibit 99.2 to this Current Report and is incorporated herein by reference. The Company plans to use its website to disseminate future updates to the Corporate Presentation and may not file or furnish a Current Report on Form 8-K alerting investors if the Corporate Presentation is updated.
The information furnished in this Item 7.01, including Exhibit 99.2, shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act, regardless of any general incorporation language in any such filings, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit |
|
Exhibit Description |
99.1 |
|
|
99.2 |
|
|
104 |
|
Cover Page Interactive Data File (formatted as Inline XBRL). |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
CLENE INC. |
|
|
|
|
Date: May 9, 2022 |
By: |
/s/ Robert Etherington |
|
|
Robert Etherington |
|
|
President and Chief Executive Officer |
2
Exhibit 99.1
Clene Reports First Quarter 2022 Financial Results and Recent Operating Highlights
SALT LAKE CITY, May 9, 2022 -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today reported its first quarter 2022 and recent operating highlights.
“As we approach the second half of 2022, we expect to report data readouts for our lead asset, CNM-Au8®, for the treatment of both ALS and MS,” said Rob Etherington, President and CEO of Clene. “Positive results from the Healey ALS Platform Trial would bring this potential new treatment option one step closer for people living with ALS.”
First Quarter 2022 and Recent Operating Highlights
CNM-Au8®, a gold nanocrystal suspension, for the treatment of amyotrophic lateral sclerosis (ALS)
CNM-Au8 for the treatment of multiple sclerosis (MS)
CNM-ZnAg for the treatment of COVID-19
First Quarter 2022 Financial Results
Clene’s cash, cash equivalents, restricted cash and marketable securities totaled $36.6 million as of March 31, 2022, compared to $50.3 million as of December 31, 2021. Clene expects that its cash as of March 31, 2022, will be sufficient to fund its operations into the second quarter of 2023.
Research and development expenses were $8.6 million for the quarter ended March 31, 2022, compared to $6.3 million for the same period in 2021. The year-over-year increase is primarily attributable to the development of CNM-Au8 and CNM-ZnAg (including the rapid completion of the COVID study due to a viral wave leading to increased patient recruitment), rent expense for the newly-leased facility in Elkton, Maryland, and personnel expenses due to increased headcount as a result primarily of increased manufacturing hours, partially offset by decreased stock-based compensation expense.
General and administrative expenses were $4.8 million for the quarter ended March 31, 2022, compared to $5.4 million for the same period in 2021. The year-over-year decrease is primarily attributable to decreased finance, accounting and consulting fees after completing the Reverse Recapitalization and related activities in early 2021 and filing a registration statement on Form S-1, and decreased stock-based compensation, partially offset by an increase in personnel compensation due to increased headcount and increased public relations and investor relations efforts.
Clene reported a net loss of $13.4 million, or $0.21 per share, for the quarter ended March 31, 2022, compared to a net loss of $39.8 million, or $0.66 per share, for the same period in 2021. Included in net loss for the quarter ended March 31, 2022, is an unrealized loss from the change in fair value of contingent earn-out liabilities of $28.6 million, compared to $69,000 in the current year period.
About Clene
Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on Twitter, LinkedIn and Facebook.
About CNM-Au8®
CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization. The catalytically active nanocrystals of CNM-Au8 drive critical cellular energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc.
About CNM-ZnAg
CNM-ZnAg, a proprietary zinc-silver ionic solution, has demonstrated broad antiviral and antimicrobial activity.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Clene’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these
forward-looking statements. Some factors that could cause actual results to differ include our substantial dependence on the successful commercialization of our drug candidates, if approved, in the future; our inability to maintain the listing of our common stock on Nasdaq; our significant net losses and net operating cash outflows; our ability to demonstrate the efficacy and safety of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our ability to obtain and maintain protection of intellectual property for our technology and drugs; our reliance on third parties to conduct drug development, manufacturing and other services; our limited operating history and our ability to obtain additional funding for operations and to complete the licensing or development and commercialization of our drug candidates; the impact of the COVID-19 pandemic on our clinical development, commercial and other operations; changes in applicable laws or regulations; the effects of inflation; the effects of staffing and materials shortages; the possibility that we may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
Media Contact |
Investor Contact |
Erica Fiorini, Ph.D., or David Schull |
John Woolford |
Russo Partners, LLC |
Managing Director, Westwicke |
Erica.fiorini@russopartnersllc.com |
clene@westwicke.com |
David.schull@russopartnersllc.com |
+1-443-213-0506 |
+1-212-845-4253 |
|
Source: Clene Inc.
CLENE INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(In thousands, except share and per share amounts)
(Unaudited)
|
|
Three Months Ended March 31, |
|
|||||
|
|
2022 |
|
|
2021 |
|
||
Revenue: |
|
|
|
|
|
|
||
Product revenue |
|
$ |
7 |
|
|
$ |
199 |
|
Royalty revenue |
|
|
23 |
|
|
|
14 |
|
Total revenue |
|
|
30 |
|
|
|
213 |
|
Operating expenses: |
|
|
|
|
|
|
||
Cost of revenue |
|
|
— |
|
|
|
243 |
|
Research and development |
|
|
8,580 |
|
|
|
6,275 |
|
General and administrative |
|
|
4,786 |
|
|
|
5,390 |
|
Total operating expenses |
|
|
13,366 |
|
|
|
11,908 |
|
Loss from operations |
|
|
(13,336 |
) |
|
|
(11,695 |
) |
Other income (expense), net: |
|
|
|
|
|
|
||
Interest expense |
|
|
(782 |
) |
|
|
(551 |
) |
Gain on extinguishment of notes payable |
|
|
— |
|
|
|
647 |
|
Gain on termination of lease |
|
|
420 |
|
|
|
— |
|
Change in fair value of common stock warrant liability |
|
|
(18 |
) |
|
|
— |
|
Change in fair value of Clene Nanomedicine contingent earn-out |
|
|
(57 |
) |
|
|
(25,610 |
) |
Change in fair value of Initial Stockholders contingent earn-out |
|
|
(12 |
) |
|
|
(2,961 |
) |
Australia research and development credit |
|
|
299 |
|
|
|
339 |
|
Other income, net |
|
|
132 |
|
|
|
3 |
|
Total other income (expense), net |
|
|
(18 |
) |
|
|
(28,133 |
) |
Net loss before income taxes |
|
|
(13,354 |
) |
|
|
(39,828 |
) |
Income tax benefit |
|
|
— |
|
|
|
72 |
|
Net loss |
|
|
(13,354 |
) |
|
|
(39,756 |
) |
|
|
|
|
|
|
|
||
Other comprehensive income (loss): |
|
|
|
|
|
|
||
Unrealized loss on available-for-sale securities |
|
|
(50 |
) |
|
|
— |
|
Foreign currency translation adjustments |
|
|
50 |
|
|
|
24 |
|
Total other comprehensive income (loss) |
|
|
— |
|
|
|
24 |
|
Comprehensive loss |
|
$ |
(13,354 |
) |
|
$ |
(39,732 |
) |
|
|
|
|
|
|
|
||
Net loss per share-- basic and diluted |
|
$ |
(0.21 |
) |
|
$ |
(0.66 |
) |
Weighted average common shares used to compute basic and diluted net loss per share |
|
|
62,852,863 |
|
|
|
60,670,932 |
|
CLENE INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
(Unaudited)
|
|
March 31, |
|
|
December 31, |
|
||
|
|
2022 |
|
|
2021 |
|
||
ASSETS |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
12,930 |
|
|
$ |
50,288 |
|
Marketable securities |
|
|
23,586 |
|
|
|
— |
|
Accounts receivable |
|
|
— |
|
|
|
49 |
|
Inventory |
|
|
38 |
|
|
|
41 |
|
Prepaid expenses and other current assets |
|
|
3,393 |
|
|
|
1,968 |
|
Metals to be used in research and development |
|
|
2,502 |
|
|
|
2,237 |
|
Total current assets |
|
|
42,449 |
|
|
|
54,583 |
|
Restricted cash |
|
|
58 |
|
|
|
58 |
|
Right-of-use assets |
|
|
4,940 |
|
|
|
3,250 |
|
Property and equipment, net |
|
|
5,914 |
|
|
|
5,172 |
|
TOTAL ASSETS |
|
$ |
53,361 |
|
|
$ |
63,063 |
|
|
|
|
|
|
|
|
||
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
3,313 |
|
|
$ |
1,923 |
|
Accrued liabilities |
|
|
1,541 |
|
|
|
3,610 |
|
Operating lease obligations, current portion |
|
|
473 |
|
|
|
347 |
|
Finance lease obligations, current portion |
|
|
139 |
|
|
|
146 |
|
Total current liabilities |
|
|
5,466 |
|
|
|
6,026 |
|
Operating lease obligations, net of current portion |
|
|
5,766 |
|
|
|
4,370 |
|
Finance lease obligations, net of current portion |
|
|
72 |
|
|
|
97 |
|
Notes payable |
|
|
14,712 |
|
|
|
14,484 |
|
Convertible notes payable |
|
|
4,655 |
|
|
|
4,598 |
|
Common stock warrant liability |
|
|
187 |
|
|
|
474 |
|
Clene Nanomedicine contingent earn-out |
|
|
18,157 |
|
|
|
18,100 |
|
Initial Stockholders contingent earn-out |
|
|
2,329 |
|
|
|
2,317 |
|
TOTAL LIABILITIES |
|
|
51,344 |
|
|
|
50,466 |
|
Commitments and contingencies (Note 12) |
|
|
|
|
|
|
||
Stockholders’ equity: |
|
|
|
|
|
|
||
Common stock, $0.0001 par value: 150,000,000 shares authorized; 63,246,545 and 62,312,097 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively |
|
|
6 |
|
|
|
6 |
|
Additional paid-in capital |
|
|
178,433 |
|
|
|
175,659 |
|
Accumulated deficit |
|
|
(176,655 |
) |
|
|
(163,301 |
) |
Accumulated other comprehensive income |
|
|
233 |
|
|
|
233 |
|
TOTAL STOCKHOLDERS’ EQUITY |
|
|
2,017 |
|
|
|
12,597 |
|
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
$ |
53,361 |
|
|
$ |
63,063 |
|
Exhibit 99.2
Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Clene’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this presentation and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include our substantial dependence on the successful commercialization of our drug candidates, if approved, in the future; our inability to maintain the listing of our common stock on Nasdaq; our significant net losses and net operating cash outflows; our ability to demonstrate the efficacy and safety of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our ability to obtain and maintain protection of intellectual property for our technology and drugs; our reliance on third parties to conduct drug development, manufacturing and other services; our limited operating history and our ability to obtain additional funding for operations and to complete the licensing or development and commercialization of our drug candidates; the impact of the COVID-19 pandemic on our clinical development, commercial and other operations; changes in applicable laws or regulations; the effects of inflation; the effects of staffing and materials shortages; the possibility that we may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this presentation, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to rely unduly upon these statements. All information in this presentation is as of the date of this presentation. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this presentation.
| Commitment and Experienced Leadership COMMITTED TO REVOLUTIONIZING TREATMENT FOR PEOPLE WITH NEURODEGENERATIVE DISEASES TO RESTORE AND PROTECT NEURONAL HEALTH
Fu, H., et al; Nature Neuroscience (2018) 21: 1350-1358. Zhu et al. Proc Natl Acad Sci USA 2015 Mar 3;112(9):2876-81. Rone et al. J Neurosci. 2016 Apr 27;36(17):4698-707. Clene is Focused on Core Brain Energy Deficits in Neurodegenerative Diseases ~0.5% NAD+/NADH unit decline per decade (~0.13 mV units per year by 31P-MRS Imaging) Brain Energy Potential Declines With Normal Aging Closed squares = averaged data by age group: 21–26 yrs, 33–36 yrs, and 59–68 yrs old; Open squares= individual subject values PARKINSON’S DISEASE Dopaminergic Neurons AMYOTROPHIC LATERAL SCLEROSIS Motor Neurons HUNTINGTON’S DISEASE Medium Spiny Neurons FRONTOTEMPORAL DEMENTIA Spindle Neurons Specific Neuronal Populations Are Vulnerable to Energetic Failure MULTIPLE SCLEROSIS Axonal Degeneration Neurons with high energetic demand are at increased risk for neurodegenerative disease
Significant Global Opportunity 1 Clarivate, DRG, ALS 2020. 2 Westad et al. 2017, doi:10.1038/nrd.2017.107;. 3 Parkinson’s Market Data Forecast, April 2021.. 4. Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 2010;67:715-725.. EMERGING EVIDENCE THAT EARLY MS IS NEURODEGENERATIVE Current drugs are largely ineffective, mostly generic. Existing treatments only target immunomodulation No disease-modifying treatments available, only symptom-targeted options OF DOPAMINERGIC NEURONS ARE LOST AT DIAGNOSIS4 Urgent unmet need to develop neuroprotective treatment to support cells’ energetic efficiency and resilience
CNM-Au8® | Catalytically-Active Nanocrystals Improves Energy Production to Promote Neuroprotection and Remyelination CNM-Au8 Nanocrystal Suspension Mechanistic Effects Improved Energy Production and Utilization Promotes Neuroprotection and Remyelination CNM-Au8 Nanocrystals Clean Surfaced, Highly Faceted Shapes Robinson et al. Sci Rep. 2020 Feb 11;10(1):1936. Data on File, Clene Nanomedicine, Inc.
CNM-Au8 Improves ALS Motor Neuron Survival & Neuron Connections Induced Pluripotent Stem Cell In Vitro Results – Motor Neuron Markers CNM-Au8® | Preclinical Evidence for Energetic Improvement Karen S. Ho et al. “Redox-enhancing nanocatalysis improves motor neuron survival in vitro and SOD1 mouse motor function and survival in vivo.” Presented at 30th International Symposium on ALS/MND 2019. December 4-6, 2019. Supports Myelin Integrity & Remyelination Robinson et al. Sci Rep. 2020 Feb 11;10(1):1936. Karen S. Ho et al. “Redox-enhancing nanocatalysis improves motor neuron survival in vitro and SOD1 mouse motor function and survival in vivo.” Presented at 30th International Symposium on ALS/MND 2019. December 4-6, 2019. CNM-Au8 enables neuroprotection and remyelination by helping nervous system cells increase their resilience to the energetic deficits driving disease progression in ALS
CNM-Au8® | Neuroprotection & Remyelination Growing Evidence Supports CNM-Au8 Clinical Potential CNM-Au8 treatment effect on ALS disease progression and potential impact on survival Established brain target engagement in early Parkinson’s Disease (PD) and stable relapsing Multiple Sclerosis (MS) Phase 2 REPAIR non-active progressive MS underway Interim blinded observations: Stable relapsing multiple sclerosis (MS) participants suggests improved function (modified MSFC) including low contrast vision Expected readout 3Q 2022 Phase 2/3 HEALEY-ALS Platform Trial Ongoing Expected readout 3Q 2022
CNM-Au8® | Safety Summary Over 350 Years of Subject Exposure Without Identified Safety Signals Patient Exposure Across PD, MS, & ALS Long-term dosing experience up to 125 weeks All Animal Toxicology Studies Resulted in No-Adverse Effect Level (NOAEL) Findings Clean Toxicology Findings Multiple species up to 9-months treatment Up to maximum feasible dosing without any toxicology findings related to CNM-Au8 Assessed as Predominantly Mild-to-Moderate Severity and Transient Well Tolerated Adverse Event (AE) Profile No SAEs related to CNM-Au8 considered severe, life-threatening, or resulting in death AEs predominantly mild-to-moderate Data on File, Clene Nanomedicine, Inc.
1. Zhu et al. Proc Natl Acad Sci USA 2015 Mar 3;112(9):2876-81.. 2. Glanzman et al Improvement of Brain Energy Metabolism in Relapsing Multiple Sclerosis Patients - Results from Phase 2 REPAIR-MS Clinical Trial With CNM-Au8, ACTRIMS February 2022 CNM-Au8® | REPAIR Program Demonstrated Target Engagement and Improved Brain Energy Metabolism Exploratory (ATP Normalization) Study Objective: to demonstrate target engagement for CNM-Au8 on CNS biomarkers related to energetic effects in the brain using Magnetic Resonance Spectroscopy (31P-MRS) 1° Endpoint (integrated PD & MS)2 Brain Energy Potential Declines With Normal Aging ~0.5% NAD+/NADH unit decline per decade in healthy people (by 31P-MRS Imaging)1 Results demonstrated 10% improvement in NAD+/NADH ratio, which may translate to decades of improvement in cellular energy production and utilization
Vucic et al. BMJ Open. 2021 Jan 11;11(1):e041479. Data on File, Clene Nanomedicine, Inc. Study obj CNM-Au8® | Evidence for Motor Neuron Protection Results in favor of CNM-Au8 treatment but study underpowered 1° & 2° Endpoints Study Objective: Detect preservation of motor neuron function in people with early ALS as measured by MUNIX By targeting energy metabolism, CNM-Au8 may be able to protect motor neurons and restore ALS function Study Design: 36-week blinded treatment with ongoing long-term open-label follow-up Bulbar Onset ALS (Brainstem) Limb Onset ALS (Spinal Cord) Primary Endpoint: Spinal Cord Lower Motor Neuron Motor Unit Index (MUNIX) Sum Biceps brachii Tibialis Anterior Abductor Pollicis Brevis Abductor Digiti Minimi + + +
Proportion with <6 point decline CNM-Au8® | Significant Impact on Key Functional ALS Measures (Exploratory Endpoint Pre-specified) 1ALS Disease Progression defined as: Death, or Tracheostomy, or Non-invasive ventilation, or Gastrostomy tube RESCUE-ALS: A Phase 2, randomized, double-blind, placebo-controlled study of CNM-Au8 to slow disease progression in ALS. MNDA Virtual Symposium, 2021. ALS Specific QOL ALS Disease Progression
CNM-Au8® | CAFS: Survival & ALSFRS-R Berry et al. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Apr;14(3):162-8. Data on File, Clene Nanomedicine, Inc. . Exploratory Endpoint Pre-specified ALSFRS-R Decline Survival CAFS King’s Clinical Stage 4 Modified CAFS Exploratory Endpoint Post Hoc
CNM-Au8® | Impact on Long-Term Survival 70% Improvement vs. ENCALS Predicted Survival (Interim Analysis) RESCUE-ALS Long-Term Observed Survival (OLE Participants) vs. ENCALS Predicted Median Survival; All Open Label Participants, Interim Analysis All OLE participants. Data censored as of 10-March-2022. Vital status and date of death (as applicable) captured for all subjects withdrawn from the study. ENCALS median survival estimate from baseline characteristics. Kiernen et al. Kiernan MC. Long-Term Survival of Randomized Participants Enrolled in the Phase 2 RESCUE-ALS Trial of CNM-Au8, A Cellular Energetic Catalyst. Presented at: AAN Annual Meeting; April 2-7, 2022;
CAFS (Joint-Rank) Survival & ALSFRS-R Slow Vital Capacity Survival Change in ALSFRS-R slope + survival Registration Study: 24-Week Treatment Period (3:1 randomization, 120 active [30mg, 60mg]: 40 placebo) 1 2 Phase 2/3 Anticipated topline data: 3Q 2022 (Stopped for futility) Paganoni et al. Ann Neurol. 2022 Feb;91(2):165-175. https://clinicaltrials.gov/ct2/show/NCT04414345.
Paganoni et al. Ann Neurol. 2022 Feb;91(2):165-175. Berry et al. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Apr;14(3):162-8. Individual Scoring ALSFRS-R Decline Survival CAFS Rank participants based on time to death or ALSFRS-R change Phase 2/3 Integrated Function & Survival 1° and Key 2° Endpoints Change in Slope of ALSFRS-R Survival Improvement (Hazard Ratio) Primary Endpoint Key Secondary Endpoint (Combined Assessment of Function & Survival) Weighted Average of (1-slope change) and Hazard Ratio (Weighting based on # of Mortality Events)
Exploratory Endpoints Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy for Assessment of Remyelination in Non-Active Relapsing MS Change in Low Contrast Letter Acuity (LCLA) At Week 24 Up to 48-Week Placebo-Control 2:1 Randomization (Active: Placebo) 15mg, 30mg, Placebo (n=73 of 150) Optical Coherence Tomography (OCT) Multi-focal VEP Amplitude & Latency Full field-VEP Amplitude & Latency MRI Endpoints Visual Function (High Contrast) QOL / EDSS 1 2 Change Composite Clinical Response 9HPT / SDMT / T25FW / LCLA Phase 2 -42 to -1 24-Week Blinded Fixed Treatment Period Up to 24-Week Blinded Extension Period (Until LPLV 24Wk Visit) LPLV Anticipated topline data: 3Q 2022 Insights to inform new Phase 2/3 MS trial https://clinicaltrials.gov/ct2/show/NCT03536559, Data on File, Clene Nanomediicne, Inc.
Significant Clinical Improvement Across Blinded Study Population Primary Endpoint: LCLA (Best-Corrected) & Secondary Endpoint: (m)MSFC Phase 2 2° | (m)MSFC 1° | LCLA Glanzman et al. VISIONARY-MS: Update to a Phase 2 Clinical Trial of CNM-Au8, Catalytically Active Gold Nanocrystals Suspension, for the Treatment of Chronic Optic Neuropathy ACTRIMS, February 2022.
1. Substantial alleviation is a patient global impression of severity scored as mild or normal. 2. Complete alleviation is a patient global impression of severity scored as normal Time to complete alleviation2 of COVID-19 symptoms through Day 28 Proportion hospitalized for COVID-19 related medical support, or are deceased Number of alive hospital free days through Day 28 Mean change in SARS-CoV-2 viral load Change in oxygen saturation slope Change in Global Impression (severity and change) Predominantly in vaccinated, symptomatic patients Time to substantial alleviation1 of COVID-19 symptoms through Day 28 https://clinicaltrials.gov/ct2/show/NCT04610138 Time to complete alleviation2 of COVID-19 symptoms through Day 28 Number of hospital free days through Day 28 Mean change in SARS-CoV-2 viral load Change in oxygen saturation slope Change in Global Impression (severity and change) Predominantly in vaccinated, symptomatic patients Time to substantial alleviation1 of COVID-19 symptoms through Day 28 Anticipated topline data: 3Q 2022
Trade Secrets Patent Status b Patent Description Issued & Allowed Patents 150+ Pending Applications ~20 Total Patents/ Applications >170 Process And Method/Device (Clean Surface; Gold CSN) State of Matter (CNM-Au8) Method of Use (Prevent Demyelination & MoA) Method of Use (Bi-Metallic Au/Pt; Antimicrobial) Plasma Conditioning Electrode Design & Cycling Trough Flow, Temp, Pressure Concentration & Filtration Strong IP & MFG Capability Extensive Patent Portfolio With Protection Through 2035a & Proprietary Trade Secrets; Plus 7-year Orphan Drug Designation, and Scalable to Commercialization a With Patent Restoration Term (assuming 5-year extension). b As of 31-December-2021. In-House ISO8 Clean Room Clinical Production in Maryland
Anticipated Timeline & Upcoming Milestones VISIONARY-MS Move data bubble to match VISIONARY March 31, 2022 Cash and investments on hand (unaudited): $36.6M
CNM-Au8® | Growing Phase 2 Evidence Supports CNM-Au8 Commercial Potential
©2022 Clene Inc. Version: 9-May-2022 Clene Inc. HQ & Clinical Development 6550 South Millrock Drive, Suite G50 Salt Lake City, UT 84121 R&D and Manufacturing 500 Principio Parkway, Suite 400 North East, MD 21901